CN104395310B - 二环取代尿嘧啶及其用途 - Google Patents

二环取代尿嘧啶及其用途 Download PDF

Info

Publication number
CN104395310B
CN104395310B CN201380034776.9A CN201380034776A CN104395310B CN 104395310 B CN104395310 B CN 104395310B CN 201380034776 A CN201380034776 A CN 201380034776A CN 104395310 B CN104395310 B CN 104395310B
Authority
CN
China
Prior art keywords
hydrogen
formula
trifluoromethyl
alkyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380034776.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN104395310A (zh
Inventor
C·菲尔斯特纳
J·埃克斯达夫
A·斯特劳布
H·迈耶
H·蒂内尔
K·齐默尔曼
A·特尔斯迪根
D·祖博夫
R·卡斯特
J·舍姆伯杰
M·沙弗尔
K·伯根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Priority to CN201710219097.9A priority Critical patent/CN106983751B/zh
Publication of CN104395310A publication Critical patent/CN104395310A/zh
Application granted granted Critical
Publication of CN104395310B publication Critical patent/CN104395310B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201380034776.9A 2012-05-09 2013-05-03 二环取代尿嘧啶及其用途 Active CN104395310B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710219097.9A CN106983751B (zh) 2012-05-09 2013-05-03 二环取代尿嘧啶及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12167231 2012-05-09
EP12167231.5 2012-05-09
PCT/EP2013/059286 WO2013167495A1 (de) 2012-05-09 2013-05-03 Bicyclisch-substituierte uracile und ihre verwendung

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710219097.9A Division CN106983751B (zh) 2012-05-09 2013-05-03 二环取代尿嘧啶及其用途

Publications (2)

Publication Number Publication Date
CN104395310A CN104395310A (zh) 2015-03-04
CN104395310B true CN104395310B (zh) 2017-05-03

Family

ID=48289199

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380034776.9A Active CN104395310B (zh) 2012-05-09 2013-05-03 二环取代尿嘧啶及其用途
CN201710219097.9A Active CN106983751B (zh) 2012-05-09 2013-05-03 二环取代尿嘧啶及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710219097.9A Active CN106983751B (zh) 2012-05-09 2013-05-03 二环取代尿嘧啶及其用途

Country Status (43)

Country Link
US (5) US9481672B2 (enExample)
EP (2) EP3045456B1 (enExample)
JP (2) JP6141414B2 (enExample)
KR (1) KR102083281B1 (enExample)
CN (2) CN104395310B (enExample)
AP (1) AP2014008096A0 (enExample)
AR (1) AR090994A1 (enExample)
AU (2) AU2013258223B2 (enExample)
BR (1) BR112014028086B1 (enExample)
CA (1) CA2872906C (enExample)
CL (1) CL2014003031A1 (enExample)
CO (1) CO7131375A2 (enExample)
CR (1) CR20140513A (enExample)
CU (1) CU20140129A7 (enExample)
CY (2) CY1118900T1 (enExample)
DK (2) DK3045456T3 (enExample)
DO (1) DOP2014000255A (enExample)
EA (2) EA031222B1 (enExample)
EC (1) ECSP14026138A (enExample)
ES (2) ES2657315T3 (enExample)
HR (2) HRP20160796T1 (enExample)
HU (2) HUE035462T2 (enExample)
IL (2) IL235438A (enExample)
JO (1) JO3290B1 (enExample)
LT (1) LT3045456T (enExample)
MX (2) MX357712B (enExample)
MY (1) MY181828A (enExample)
NO (1) NO3045456T3 (enExample)
NZ (1) NZ701700A (enExample)
PE (1) PE20142301A1 (enExample)
PH (1) PH12014502496B1 (enExample)
PL (2) PL2847190T3 (enExample)
PT (2) PT3045456T (enExample)
RS (2) RS54901B1 (enExample)
SA (1) SA113340533B1 (enExample)
SG (1) SG10202003175QA (enExample)
SI (2) SI3045456T1 (enExample)
TN (1) TN2014000470A1 (enExample)
TW (2) TWI635085B (enExample)
UA (1) UA112897C2 (enExample)
UY (1) UY34797A (enExample)
WO (1) WO2013167495A1 (enExample)
ZA (1) ZA201408146B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106983751A (zh) * 2012-05-09 2017-07-28 拜耳医药股份有限公司 二环取代尿嘧啶及其用途

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2929753A1 (en) * 2013-11-08 2015-05-14 Bayer Pharma Aktiengesellschaft Substituted uracils and use thereof
HK1224288A1 (zh) * 2013-11-08 2017-08-18 Bayer Pharma Aktiengesellschaft 作为类糜蛋白酶抑制剂的取代的尿嘧啶
SI3066097T1 (sl) * 2013-11-08 2017-12-29 Bayer Pharma Aktiengeselschaft Soli 1-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-6-il)-2,4-diokso-3-((1r)-4 -(trifluormetil)-2,3-dihidro-1H-inden-1-il)-1,2,3,4-tetrahidropirimidin- 5-ogljikove kisline
HK1223610A1 (zh) * 2013-11-08 2017-08-04 Bayer Pharma Aktiengesellschaft 取代的1，2，4-三嗪-3，5-二酮及其作为类糜蛋白酶抑制剂的用途
WO2017162661A1 (en) 2016-03-22 2017-09-28 Bayer Pharma Aktiengesellschaft 1h-benzo[de]isoquinoline-1,3(2h)-diones
EP3338780A1 (de) * 2016-12-20 2018-06-27 Bayer Pharma Aktiengesellschaft Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind
CA3061444A1 (en) 2017-04-27 2018-11-01 Bayer Aktiengesellschaft Selective adrenoreceptor .alpha.2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad)
BR112020022340A2 (pt) 2018-05-15 2021-02-02 Bayer Aktiengesellschaft benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas
CN110229067A (zh) * 2019-06-05 2019-09-13 南京焕然生物科技有限公司 一种2-氨基茚制备方法
CN113811530B (zh) * 2019-07-03 2022-07-19 南京明德新药研发有限公司 作为糜酶抑制剂的嘧啶酮类化合物及其应用
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
CN111440141A (zh) * 2020-05-20 2020-07-24 安徽泽升科技有限公司 一种羟甲基取代芳杂环类化合物的制备方法
WO2022135502A1 (zh) * 2020-12-25 2022-06-30 广东东阳光药业有限公司 多取代的尿嘧啶衍生物及其用途
WO2022135514A1 (zh) * 2020-12-25 2022-06-30 广东东阳光药业有限公司 多取代的尿嘧啶衍生物及其用途
WO2022135534A1 (zh) * 2020-12-25 2022-06-30 广东东阳光药业有限公司 取代的含氮双环化合物及其用途
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
US20250051367A1 (en) * 2021-12-06 2025-02-13 Pretzel Therapeutics, Inc. Heterocycle-containing lonp1 inhibitor compounds, uses and methods
CN119278042A (zh) * 2022-04-05 2025-01-07 索克普拉健康与人文科学公司 用于血栓性或血栓栓塞性病症中血栓的选择性溶解的糜蛋白酶抑制剂
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003342265A (ja) * 2002-05-22 2003-12-03 Senju Pharmaceut Co Ltd トリアゾリジン誘導体およびその医薬用途
CN1471528A (zh) * 2000-08-30 2004-01-28 �ձ���ҩ��ʽ���� 吡咯烷衍生物及它们作为食糜酶抑制剂的用途
CN1871029A (zh) * 2003-08-22 2006-11-29 帝人制药株式会社 含有类糜蛋白酶抑制剂作为有效成分的药物
CN101505752A (zh) * 2006-06-23 2009-08-12 史密丝克莱恩比彻姆公司 脯氨酸羟化酶抑制剂
WO2009156182A2 (de) * 2008-06-25 2009-12-30 Resprotect Gmbh Uracilderivate und deren verwendung

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US6114532A (en) 1998-02-03 2000-09-05 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
US6458952B1 (en) 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
EP1219611A4 (en) 1999-09-03 2003-03-19 Ajinomoto Kk NEW PROCESSES FOR THE PRODUCTION OF OXAZEPINE DERIVATIVES
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
JP2003017508A (ja) 2001-07-05 2003-01-17 Nec Corp 電界効果トランジスタ
AR038536A1 (es) 2002-02-25 2005-01-19 Upjohn Co N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
AU2003290735A1 (en) 2002-12-06 2004-06-30 Eli Lilly And Company Inhibitors of monoamine uptake
DE102004004928A1 (de) 2004-01-31 2005-08-18 Bayer Healthcare Ag Dibenzoxazepine II
WO2005092899A1 (en) 2004-03-26 2005-10-06 Methylgene Inc. Inhibitors of histone deacetylase
US7507748B2 (en) 2004-07-22 2009-03-24 Amgen Inc. Substituted aryl-amine derivatives and methods of use
US20070078121A1 (en) 2004-12-23 2007-04-05 Flynn Daniel L Enzyme modulators and treatments
WO2006119504A2 (en) 2005-05-04 2006-11-09 Renovis, Inc. Fused heterocyclic compounds, and compositions and uses thereof
WO2007007161A2 (en) * 2005-07-08 2007-01-18 Orchid Research Laboratories Limited Novel bio-active derivatives
WO2007120339A1 (en) 2005-12-19 2007-10-25 Genentech, Inc. Pyrimidine kinase inhibitors
ES2331930T3 (es) 2006-02-14 2010-01-20 Pfizer Products Inc. Oxazolidinonas con benzoxazinonas y benzoxazepinonas como agentes antibacterianos.
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
GB0622472D0 (en) 2006-11-10 2006-12-20 Addex Pharmaceuticals Sa Novel heterocyclic derivatives
AU2008219166B2 (en) 2007-02-16 2013-05-16 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
CA2683785A1 (en) 2007-04-13 2008-10-23 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
MX2010003346A (es) 2007-10-19 2010-04-09 Boehringer Ingelheim Int Piperazino-dihidrotienopirimidinas sustituidas en heterociclo.
CN102015682B (zh) * 2008-05-05 2014-07-16 埃科特莱茵药品有限公司 作为肾素抑制剂的3,4-取代的哌啶衍生物
CA2727340A1 (en) 2008-06-25 2009-12-30 Daiichi Sankyo Company, Limited Carboxylic acid compound
UA112897C2 (uk) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1471528A (zh) * 2000-08-30 2004-01-28 �ձ���ҩ��ʽ���� 吡咯烷衍生物及它们作为食糜酶抑制剂的用途
JP2003342265A (ja) * 2002-05-22 2003-12-03 Senju Pharmaceut Co Ltd トリアゾリジン誘導体およびその医薬用途
CN1871029A (zh) * 2003-08-22 2006-11-29 帝人制药株式会社 含有类糜蛋白酶抑制剂作为有效成分的药物
CN101505752A (zh) * 2006-06-23 2009-08-12 史密丝克莱恩比彻姆公司 脯氨酸羟化酶抑制剂
WO2009156182A2 (de) * 2008-06-25 2009-12-30 Resprotect Gmbh Uracilderivate und deren verwendung

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106983751A (zh) * 2012-05-09 2017-07-28 拜耳医药股份有限公司 二环取代尿嘧啶及其用途

Also Published As

Publication number Publication date
TN2014000470A1 (en) 2016-03-30
TW201734007A (zh) 2017-10-01
JO3290B1 (ar) 2018-09-16
WO2013167495A1 (de) 2013-11-14
DOP2014000255A (es) 2015-02-27
EP2847190A1 (de) 2015-03-18
US10300062B2 (en) 2019-05-28
ZA201408146B (en) 2017-01-25
EA201492040A1 (ru) 2015-12-30
SI2847190T1 (sl) 2016-08-31
US20150148340A1 (en) 2015-05-28
US20180256576A1 (en) 2018-09-13
PL3045456T3 (pl) 2018-03-30
CR20140513A (es) 2014-12-02
CO7131375A2 (es) 2014-12-01
IL235438A (en) 2017-08-31
AU2017265047A1 (en) 2017-12-14
EP3045456A1 (de) 2016-07-20
HK1202873A1 (en) 2015-10-09
CU20140129A7 (es) 2015-02-26
SG10202003175QA (en) 2020-05-28
CN104395310A (zh) 2015-03-04
CL2014003031A1 (es) 2015-03-06
KR20150016548A (ko) 2015-02-12
KR102083281B1 (ko) 2020-05-29
MX357712B (es) 2018-07-20
ECSP14026138A (es) 2015-12-31
JP2015516000A (ja) 2015-06-04
HRP20180125T1 (hr) 2018-02-23
UY34797A (es) 2013-11-29
PL2847190T3 (pl) 2016-12-30
DK2847190T3 (en) 2016-07-25
AR090994A1 (es) 2014-12-30
LT3045456T (lt) 2018-02-12
US9949978B2 (en) 2018-04-24
SA113340533B1 (ar) 2015-10-12
TWI579278B (zh) 2017-04-21
ES2657315T3 (es) 2018-03-02
MX367599B (es) 2019-08-28
BR112014028086A2 (pt) 2020-12-01
EA201790032A1 (ru) 2017-05-31
CY1118900T1 (el) 2018-01-10
CY1119840T1 (el) 2018-06-27
SI3045456T1 (en) 2018-03-30
RS56784B1 (sr) 2018-04-30
PT3045456T (pt) 2018-01-30
NO3045456T3 (enExample) 2018-03-24
EP2847190B1 (de) 2016-04-06
JP2017160242A (ja) 2017-09-14
EA030383B9 (ru) 2018-12-28
PH12014502496A1 (en) 2015-01-12
PT2847190T (pt) 2016-07-14
US9949977B2 (en) 2018-04-24
AU2013258223A1 (en) 2014-11-27
CN106983751B (zh) 2020-01-07
PE20142301A1 (es) 2014-12-19
HRP20160796T1 (hr) 2016-08-12
DK3045456T3 (da) 2018-01-29
AU2013258223B2 (en) 2017-11-09
NZ701700A (en) 2016-09-30
HUE035462T2 (en) 2018-05-02
CN106983751A (zh) 2017-07-28
CA2872906A1 (en) 2013-11-14
TW201406744A (zh) 2014-02-16
US20170020876A1 (en) 2017-01-26
JP6367421B2 (ja) 2018-08-01
EA031222B1 (ru) 2018-12-28
ES2581537T3 (es) 2016-09-06
EP3045456B1 (de) 2017-10-25
MY181828A (en) 2021-01-08
IL253950A0 (en) 2017-10-31
BR112014028086B1 (pt) 2021-09-21
IL253950B (en) 2019-07-31
AU2017265047B2 (en) 2019-04-18
TWI635085B (zh) 2018-09-11
EA030383B1 (ru) 2018-07-31
PH12014502496B1 (en) 2015-01-12
RS54901B1 (sr) 2016-10-31
US20170020875A1 (en) 2017-01-26
US9481672B2 (en) 2016-11-01
HUE029366T2 (en) 2017-02-28
AP2014008096A0 (en) 2014-12-31
UA112897C2 (uk) 2016-11-10
JP6141414B2 (ja) 2017-06-07
MX2014013571A (es) 2014-12-08
CA2872906C (en) 2020-08-04
US20200061063A1 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
CN104395310B (zh) 二环取代尿嘧啶及其用途
HK1224288A1 (zh) 作为类糜蛋白酶抑制剂的取代的尿嘧啶
US9751843B2 (en) Substituted uracils and use thereof
HK1202873B (en) Bicyclically substituted uracils and the use thereof
HK1224663A1 (zh) 取代的尿嘧啶及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1202873

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: Berlin

Patentee after: Bayer Pharma AG

Address before: Berlin

Patentee before: Bayer medicine company stock company

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1202873

Country of ref document: HK